Left Menu
Development News Edition

GSK aims for 1 bln doses of booster as COVID-19 vaccine race heats up

Reuters | London | Updated: 28-05-2020 18:25 IST | Created: 28-05-2020 17:18 IST
GSK aims for 1 bln doses of booster as COVID-19 vaccine race heats up
Representative image Image Credit: ANI

GSK, the world's largest vaccine maker, laid out plans on Thursday to produce 1 billion doses of vaccine efficacy boosters for COVID-19 shots next year, as the race to develop a successful solution to the coronavirus crisis heats up.

The British drugmaker said it was in talks with governments to back the manufacturing expansion of the boosters, or adjuvants, that would help to scale up production of future vaccines for COVID-19, the disease caused by the novel coronavirus. The adjuvant could be a critical ingredient in at least seven experimental vaccines against the new coronavirus currently being developed around the world, including one by Sanofi, with whom GSK signed a collaboration deal in April.

Adjuvants, a key component of the traditional vaccination approach, have been shown to create stronger and longer-lasting immunity against infections and allow for lower dosing of the protein in a vaccine, making way for higher-volume production. GSK would not disclose the program's costs, saying only that production would take place at sites in Europe and North America and that it would reinvest any profit into coronavirus research and preparation for future pandemics.

The company is one of the many global players working on projects to counter the respiratory illness that currently that has no treatment and has killed about 350,000 people. "We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so," said GSK Global Vaccines President Roger Connor.

As well as its collaboration with Sanofi, GSK has contributed the adjuvant to alliances involving Chinese biotech firms Clover Biopharmaceuticals and Xiamen Innovax, as well as the University of Queensland, Australia. GSK shares were up 1.4% at 1,671.2 pence by 0916 GMT.

BOOSTER SHOT Experts have predicted that a successful vaccine will take more than a year to develop. Companies and governments are pouring money into dozens of programs as their best hope of allowing an escape from lockdowns and getting economies expanding again.

While more than 100 vaccine candidates are being trialed, according to the World Health Organisation only 10 have moved to test in humans, a stage where they are investigated for safety and efficacy, and at which most vaccines fail. Other promising vaccine approaches do without adjuvants. These include the use of so-called mRNA, pursued by Moderna and Biotech, where genetic code is injected into the body to instruct human cells to make virus-like proteins that trigger an immune response.

AstraZeneca and Oxford University's viral vector approach, where harmless viruses instruct human cells to make virus-like proteins, also needs no adjuvants. The United States last week secured almost a third of the first 1 billion doses planned for AstraZeneca's experimental COVID-19 vaccine by pledging up to $1.2 billion.

On Thursday GSK said that making its adjuvant available to the world's poorest countries will be a key part of its efforts.



Why COVID-19 is unstoppable in USA despite it being ranked at the top of GHS Index?

Several worst-hit countries such as Italy, France, Spain, the UK, Canada, and Russia have peaked COVID-19 cases in April. Almost all of them have gradually flattened the curve. However, the USA is setting new daily records of infections tha...

COVID-19 seems cooking biggest ever global scam

The increasing number of corruption cases on COVID-19 funds from throughout the world and involvement of high profile persons indicate that the countries cant ignore corruption in their pandemic response programs. This has generated the nee...

Health Management Information Systems lack holistic, integrated, and pandemic resilient character

Being a part of the United Nations system, the World Health Organization WHO deserves its share of rebuke for its alleged failure issue COVID-19 health emergency alerts on appropriate time. However, the pandemic has also exposed loopholes i...

Pride in the time of coronavirus: a welcome move online?

This year is different in many ways not least as celebrations are also taking place against the dramatic backdrop of a global health crisis and a resurgence in grassroots activism following the death of George Floyd in Minneapolis. ...


Latest News

Equity indices subdued, Nifty PSU bank up 3.2 pc

Equity benchmark indices were flat with a negative bias during early hours on Wednesday tracking mixed Asian cues and the India-China geopolitical de-escalation. However, a continued surge in coronavirus cases cast doubts over the economic ...

AICF secretary Chauhan hits out at Raja faction after chief selector's resignation

All India Chess Federation AICF secretary Bharat Singh Chauhan has hit out at rival P R Venketrama Raja factions allegations that he prompted the resignation of chief selector R B Ramesh and urged the Grandmaster to clear the air. Ramesh on...

Indian police arrest 12 officials of LG Polymers over blast

Indian police have arrested 12 LG Polymers officials, including its chief executive and two directors, an officer said on Wednesday, two months after a deadly gas leak at the companys south India chemical plant killed 12. A total of twelve ...

Union Cabinet meeting to be held today

Union Cabinet meeting will be held on Wednesday at 7, Lok Kalyan Marg Prime Ministers residence.On June 24, the Union Cabinet had approved setting up of Animal Husbandry Infrastructure Development Fund AHIDF amounting to Rs 15,000 crore.Aft...

Give Feedback